logo-loader
viewKazia Therapeutics Ltd

Kazia Therapeutics directors buy more shares through on-market trades

Kazia had a transformational year in 2019 with initial clinical efficacy read-outs from both its key R&D programs.

Kazia Therapeutics Ltd - Kazia Therapeutics directors buy more shares through on-market trades
The clinical trial results translated into a material re-rating of the company’s valuation.

Kazia Therapeutics Ltd (ASX:KZA) CEO Dr James Garner and director Steven Coffey have increased their shareholding in the company by purchasing shares on market.

Dr Garner acquired 15,000 shares and Coffey bought 10,000 shares to increase their holdings to 200,000 and 251,474 respectively.

Initial success for key R&D programs

Kazia had a transformational year in 2019 with initial clinical efficacy read-outs from both its key R&D programs.

This included initial data from the ongoing phase 2 clinical trial of GDC-0084 (paxalisib) in glioblastoma which showed concrete signals of clinical efficacy.

2019 was also a positive year for the Cantrixil program, with positive data reported from the ongoing phase I study in ovarian cancer

These clinical trial results translated into a material re-rating of the company’s valuation.

On January 1 2019 Kazia shares traded at 34 cents. On December 31 2019 they traded at 60 cents.

Quick facts: Kazia Therapeutics Ltd

Price: 0.445 AUD

ASX:KZA
Market: ASX
Market Cap: $32.11 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kazia Therapeutics Ltd named herein, including the promotion by the Company of Kazia Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Kazia Therapeutics releases data from study of GDC-0084 into...

Kazia Therapeutics Ltd (ASX:KZA) chief executive officer Dr James Garner updates Proactive on the release of positive key interim data from the company's ongoing phase II study of GDC-0084 in glioblastoma, the most common and most aggressive form of primary brain cancer. Dr Garner explains...

on 11/24/2019

2 min read